MoneyWorks4Me

Torrent Pharmaceuticals enters into patent licensing agreement with Takeda

05 Jun 2024 Evaluate

Torrent Pharmaceuticals has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceuticals (Takeda) to commercialize Vonoprazan in India. Vonoprozan is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of acid related disorders - Gastroesophageal Reflux Disease (GERD). Torrent will market Vonoprazan under its own trademark, Kabvie. 

Torrent Pharmaceuticals is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.


Peers
Company Name CMP
Sun Pharma. Inds. 1756.90
Dr. Reddys Labs. 1195.10
Cipla 1303.30
Lupin 1960.00
Zydus Lifesciences 1115.10
View more..